Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanislovas S Jankauskas

Showing results (1-10 of 112) with videos related to

Pageof 12
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|December 29, 2022
Istaroxime and Beyond: New Therapeutic Strategies to Specifically Activate SERCA and Treat Heart FailureRoberta Avvisato, Stanislovas S Jankauskas, Gaetano Santulli
Cellular and Molecular Life Sciences : CMLS|July 27, 2022
From resveratrol to ISIDE11: how to activate SIRT1 and improve endothelial function? New therapeutic insights for methylenetetrahydrofolate reductase deficiencyStanislovas S Jankauskas, Pasquale Mone, Gaetano Santulli
Diabetes|May 20, 2026
Hippo-YAP Signaling Drives Epigenetic Vulnerability in the Diabetic Heart via the miR-22-3p-SIRT1 Axis: Linking Metabolic Stress to Chromatin ControlStanislovas S Jankauskas, Fahimeh Varzideh, Gaetano Santulli
European Heart Journal. Cardiovascular Pharmacotherapy|March 3, 2021
Inclisiran: a new milestone on the PCSK9 road to tackle cardiovascular riskGaetano Santulli, Stanislovas S Jankauskas, Jessica Gambardella
Journal of Molecular and Cellular Cardiology Plus|January 13, 2025
Targeting miR-199a reduces fibrosis in hypertrophic cardiomyopathyStanislovas S Jankauskas, Fahimeh Varzideh, Urna Kansakar, et al.
Frontiers in Cardiovascular Medicine|January 9, 2023
Aprocitentan: New insightsFahimeh Varzideh, Urna Kansakar, Stanislovas S Jankauskas, et al.
Journal of Personalized Medicine|April 27, 2026
Artificial Intelligence in Cardiovascular Medicine: A Giant Step in Personalized Medicine?Stanislovas S Jankauskas, Fahimeh Varzideh, Urna Kansakar, et al.
Journal of Cardiovascular Pharmacology|June 25, 2025
Comparative LDL-C Lowering Efficacy of Non-Statin Therapies: Inclisiran is Better than Ezetimibe, PCSK9 inhibitors, and Bempedoic AcidGaetano Santulli, Urna Kansakar, Stanislovas S Jankauskas, et al.
Atherosclerosis|April 9, 2021
Targeting the phenotypic switch of vascular smooth muscle cells to tackle atherosclerosisUrna Kansakar, Stanislovas S Jankauskas, Jessica Gambardella, et al.
Hypertension (Dallas, Tex. : 1979)|January 21, 2026
IL-33 Drives Endothelial-to-Mesenchymal Transition in Pulmonary HypertensionStanislovas S Jankauskas, Urna Kansakar, Fahimeh Varzideh, et al.
Pageof 12

Showing results (1-10 of 112) with videos related to

Sort By:
Pageof 12
The Journal of Pharmacology and Experimental Therapeutics|December 29, 2022
Istaroxime and Beyond: New Therapeutic Strategies to Specifically Activate SERCA and Treat Heart FailureRoberta Avvisato, Stanislovas S Jankauskas, Gaetano Santulli
Cellular and Molecular Life Sciences : CMLS|July 27, 2022
From resveratrol to ISIDE11: how to activate SIRT1 and improve endothelial function? New therapeutic insights for methylenetetrahydrofolate reductase deficiencyStanislovas S Jankauskas, Pasquale Mone, Gaetano Santulli
Diabetes|May 20, 2026
Hippo-YAP Signaling Drives Epigenetic Vulnerability in the Diabetic Heart via the miR-22-3p-SIRT1 Axis: Linking Metabolic Stress to Chromatin ControlStanislovas S Jankauskas, Fahimeh Varzideh, Gaetano Santulli
European Heart Journal. Cardiovascular Pharmacotherapy|March 3, 2021
Inclisiran: a new milestone on the PCSK9 road to tackle cardiovascular riskGaetano Santulli, Stanislovas S Jankauskas, Jessica Gambardella
Journal of Molecular and Cellular Cardiology Plus|January 13, 2025
Targeting miR-199a reduces fibrosis in hypertrophic cardiomyopathyStanislovas S Jankauskas, Fahimeh Varzideh, Urna Kansakar, et al.
Frontiers in Cardiovascular Medicine|January 9, 2023
Aprocitentan: New insightsFahimeh Varzideh, Urna Kansakar, Stanislovas S Jankauskas, et al.
Journal of Personalized Medicine|April 27, 2026
Artificial Intelligence in Cardiovascular Medicine: A Giant Step in Personalized Medicine?Stanislovas S Jankauskas, Fahimeh Varzideh, Urna Kansakar, et al.
Journal of Cardiovascular Pharmacology|June 25, 2025
Comparative LDL-C Lowering Efficacy of Non-Statin Therapies: Inclisiran is Better than Ezetimibe, PCSK9 inhibitors, and Bempedoic AcidGaetano Santulli, Urna Kansakar, Stanislovas S Jankauskas, et al.
Atherosclerosis|April 9, 2021
Targeting the phenotypic switch of vascular smooth muscle cells to tackle atherosclerosisUrna Kansakar, Stanislovas S Jankauskas, Jessica Gambardella, et al.
Hypertension (Dallas, Tex. : 1979)|January 21, 2026
IL-33 Drives Endothelial-to-Mesenchymal Transition in Pulmonary HypertensionStanislovas S Jankauskas, Urna Kansakar, Fahimeh Varzideh, et al.
Pageof 12